Core Insights - NKGen Biotech, Inc. has received a significant investment of $2.65 million from its Chairman & CEO, Dr. Paul Y. Song, to support its Phase 2 clinical trial for Alzheimer's Disease and to address financial obligations [2][3] - The company has also secured approximately $3 million in funding advances from AlpineBrook Capital, which is intended to bolster its core operations and financial reporting requirements [4][5] Funding Details - Dr. Song's investment was made in the form of common stock and warrants, reflecting his confidence in the company's long-term growth prospects [3] - The total funding from AlpineBrook includes $3 million in advances and previous commitments of $5.5 million from convertible notes, along with an additional $4 million [1][4] Company Strategy - The new capital is crucial for NKGen to ramp up its Phase 2 trial and meet public company compliance requirements, which are essential for its long-term success [3][4] - Dr. Song emphasized the alignment of interests between the management team and investors, showcasing a strong commitment to the company's vision and potential [4]

Core Viewpoint - NKGen Biotech, Inc. has been notified of its delisting from the Nasdaq Global Market due to non-compliance with market value requirements, and will transition to trading on the OTC Markets starting March 5, 2025 [1][6] Company Developments - The company will not proceed with a previously announced 1-for-6 reverse stock split following the move away from Nasdaq [2] - NKGen has faced significant challenges related to the financial restructuring of its former parent company, NKMAX, Co. Ltd., but maintains confidence in its scientific approach to treating neurodegenerative diseases [3] - The company has received U.S. FDA Fast Track designation for its innovative NK cell therapies and has presented promising data at major Alzheimer's conferences [3] - NKGen aims to complete enrollment in its Phase 2a Alzheimer's clinical trial by the end of Q2 2025, with preliminary results expected later in the year [6] Trading Information - NKGen's common stock and warrants will trade on the OTCQX platform under the ticker symbols "NKGN" and "NKGNW" respectively [1][6] - The company has regained compliance with SEC public reporting obligations as of March 4, 2025, and intends to maintain these obligations during its transition [6]

__________________________________________ NKGen Biotech, Inc. (Exact name of registrant as specified in its charter) __________________________________________ | (State or other jurisdiction of | | --- | | incorporation or organization) | As filed with the United States Securities and Exchange Commission on June 27, 2024. Registration No. 333-275094 (Commission File Number) (I.R.S. Employer UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STAT ...

As filed with the United States Securities and Exchange Commission on May 13, 2024. Registration No. 333-275094 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________________ NKGen Biotech, Inc. (Exact name of registrant as specified in its charter) __________________________________________ Delaware 001-40427 86-2191918 Identification Number) 3001 Daimler St. Santa Ana, Ca ...

Table of Contents As filed with the United States Securities and Exchange Commission on October 19, 2023. NKGen Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisdiction of incorporation or organization) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Commission File Number) (I.R.S. Employer Identification Number) 3001 Daimler S ...